Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 13/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493574 | 0.89 | GSK3B (0.54) | GSK3BNPC1RAB9AALDH1A1 | |
| SCHEMBL3491224 | 0.87 | GSK3B (0.64) | GSK3B | |
| SCHEMBL3490023 | 0.81 | GSK3B (0.53) | GSK3BSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL3491029 | 0.80 | GSK3B (0.60) | GSK3BSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL3492069 | 0.80 | GSK3B (0.50) | GSK3BSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL3492680 | 0.79 | GSK3B (0.58) | GSK3BSMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL3490700 | 0.79 | GSK3B (0.61) | GSK3B | |
| SCHEMBL3490425 | 0.78 | GSK3B (0.55) | GSK3BSMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL3490452 | 0.78 | GSK3B (0.53) | GSK3BSMN1; SMN2RAB9AHPGDMAPT | |
| SCHEMBL3490840 | 0.78 | GSK3B (0.55) | GSK3BSMN1; SMN2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | GSK3B 1/4885SMN1; SMN2 1036/4885NPC1 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.